NMIBC Management

Improve Detection, Reduce Recurrence -
Combine NBI and PLASMA for the Optimal Clinical Outcome

Contact us

Optimised Solution for Early Diagnosis of Bladder Cancer

HD NBI Videocystoscopy Is Setting the New Standard in Bladder Cancer Diagnosis and Follow-Up

Olympus offers the optimised solution for outpatient departments.

  • The outpatient imaging platform CV-170 allows cost-effective access to the power of HD and NBI in endoscopic diagnosis in urology
  • High-resolution HDTV images deliver sharp and clear details, improving observation capabilities when examining mucosal structures and additional vessel patterns
  • The revolutionary CYF-VH Videocystoscope provides a HD image, offering NBI for better detection and improved patient comfort

NBI Is Proven for Better Clinical Outcomes

Flexible cystoscopy either for early diagnosis or follow-up procedures can be performed using NBI in an outpatient setting. It is clinically proven that NBI diagnoses more bladder cancer compared to WLI. Explore procedure videos showing the clinical advantages NBI can offer in flexible cystoscopy. No matter whether you perform initial diagnosis or follow-up cystoscopies, NBI allows you to enhance the contrast and achieve a new perspective with additional details not visible before.

NBI and PLASMA for Bladder Cancer Management

The Combination of NBI and PLASMA Optimises the Outcome of NMIBC Treatment

When NBI and PLASMA are used during TUR-BT, diagnosis and therapy of NMIBC can be performed simultaneously. The combination of the two technologies – NBI and PLASMA – during TUR-BT leads to an optimal clinical outcome. With NBI, lesion limits can be better visualised. This allows precise marking in the first step as well as even complete resection of the bladder tumour using the PLASMA technology. Surgeons can choose from a wide variety of PLASMA electrodes that are procedure-specific for conventional as well as en bloc resection.

“A better view of superficial structures provides me with strong leverage for improving the detection rate of small superficial bladder tumours. But with NBI, it is not only easier to identify the malignant structures of NMIBC and other small tumours. NBI has a great impact on finding out whether a suspicious structure is inflammation or a CIS!”

Professor Jørgen Bjerggaard Jensen Department of Urology at Aarhus University Hospital
Chairman of the Danish Bladder Cancer Group

Related Products

VISERA ELITE III

VISERA ELITE III is the endoscopic visualisation platform with software upgrades and technology that allows you to focus on your procedures, while significantly reducing future costs.

Improve Your Clinical Outcomes in NMIBC Management

Increase your detection rate and optimise your treatment of NMIBC using Olympus NBI and PLASMA technology. Send us a request and an Olympus representative will contact you.

Your message

Olympus respects your privacy. Please see our Privacy Notice for information on how we process your personal data for replying to your query.
* required field

References

  1. 1.Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials Sylvester RJ et al. J Urol 2002; 168:1964–1970.
  2. 2.Fluorescence Cystoscopy in the Management of Bladder Cancer: A Help for the Urologist! Jichlinski P et al. Urol. Int. 2005; 74:97–101
  3. 3.Narrow Band Imaging-assisted transurethral resection reduces the recurrence risk of nonmuscle invasive bladder cancer: A systematic review and meta-analysis Kang W et al. Oncotarget. 2016 Nov 03
  4. 4.Diagnosis of Narrow Band Imaging in Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis Li K et al. International Journal of Urology 2013; 20:602–609
  5. 5.A Comparison of NBI and WLI Cystoscopy in Detecting Non-muscle-invasive Bladder Cancer: A Prospective, Randomized and Multi-center Study Ye Z et al. Sci Rep. 2015; 5; 10905
  6. 6.EAU Guidelines on Non-muscle-invasive Bladder Cancer. Babjuk M et al. European Association of Urology (EAU), paragraph 5.11.2, EAU Guidelines Office, March 2017
  7. 7.Bladder cancer: diagnosis and management NICE guideline. Bagnall P et al. Published 25 February 2015, retrieved on 20 February 2017
  8. 8.Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Joint Guideline Chang SS et al. Retrieved on 20 February 2017
  9. 9.A Network Meta-analysis of Therapeutic Outcomes After new Image Technology-Assisted Transurethral Resection for Nonmuscle Invasive Bladder Cancer: 5-Aminolaevulinic Acid Fluorescence vs Hexylaminolevulinate Fluorescence vs Narrow-band imaging Lee JY et al. BMC Cancer 2015; 15: 566
  10. 10.A Randomized Prospective Trial to Assess the Impact of Transurethral Resection in Narrow Band Imaging Modality on Non–Muscle-Invasive Bladder Cancer Recurrence Puppo P et al. European Urology 2012; 61:908–913
  11. 11.Narrow Band Imaging Digital Flexible Ureteroscopy in Detection of Upper Urinary Tract Transitional-Cell Carcinoma: Initial Experience Traxer O et al. J Endourol. 2011 Jan;25(1):19-23